What is William Blair’s Forecast for SLN FY2027 Earnings?

Silence Therapeutics plc (NASDAQ:SLN) – Equities research analysts at William Blair boosted their FY2027 earnings estimates for Silence Therapeutics in a research report issued on Thursday, May 8th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of $13.66 for the year, up from their previous estimate of $13.57. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics’ FY2028 earnings at $24.35 EPS.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group reduced their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a research note on Friday, May 9th. BMO Capital Markets reduced their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. Chardan Capital reduced their price target on shares of Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Morgan Stanley reduced their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.83.

Silence Therapeutics Stock Performance

Silence Therapeutics stock opened at $4.11 on Monday. The company’s 50 day simple moving average is $3.36 and its 200-day simple moving average is $6.30. The company has a market capitalization of $123.01 million, a price-to-earnings ratio of -2.62 and a beta of 1.20. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $24.38.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP grew its holdings in shares of Silence Therapeutics by 190.3% in the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock valued at $3,364,000 after purchasing an additional 320,472 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Silence Therapeutics during the 4th quarter worth approximately $26,000. Nantahala Capital Management LLC grew its holdings in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after acquiring an additional 849,676 shares in the last quarter. Trexquant Investment LP acquired a new position in Silence Therapeutics during the 4th quarter worth approximately $438,000. Finally, Cantor Fitzgerald L. P. grew its holdings in Silence Therapeutics by 61.5% during the 4th quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company’s stock worth $3,713,000 after acquiring an additional 205,534 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.